These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15912960)

  • 1. Cathepsin S inhibitors as novel immunomodulators.
    Thurmond RL; Sun S; Karlsson L; Edwards JP
    Curr Opin Investig Drugs; 2005 May; 6(5):473-82. PubMed ID: 15912960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a potent and selective noncovalent cathepsin S inhibitor.
    Thurmond RL; Sun S; Sehon CA; Baker SM; Cai H; Gu Y; Jiang W; Riley JP; Williams KN; Edwards JP; Karlsson L
    J Pharmacol Exp Ther; 2004 Jan; 308(1):268-76. PubMed ID: 14566006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in cathepsin S inhibitor design.
    Link JO; Zipfel S
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):471-82. PubMed ID: 16889230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the roles of cathepsins in antigen processing and presentation revealed by specific inhibitors.
    Katunuma N; Matsunaga Y; Himeno K; Hayashi Y
    Biol Chem; 2003 Jun; 384(6):883-90. PubMed ID: 12887055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin L maturation and activity is impaired in macrophages harboring M. avium and M. tuberculosis.
    Nepal RM; Mampe S; Shaffer B; Erickson AH; Bryant P
    Int Immunol; 2006 Jun; 18(6):931-9. PubMed ID: 16636015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity.
    Desai SN; White DM; O'shea KM; Brown ML; Cywin CL; Spero DM; Panzenbeck MJ
    Eur J Pharmacol; 2006 May; 538(1-3):168-74. PubMed ID: 16631730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-presentation: underlying mechanisms and role in immune surveillance.
    Rock KL; Shen L
    Immunol Rev; 2005 Oct; 207():166-83. PubMed ID: 16181335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cysteine cathepsin S as an immunomodulatory target: present and future trends.
    Gupta S; Singh RK; Dastidar S; Ray A
    Expert Opin Ther Targets; 2008 Mar; 12(3):291-9. PubMed ID: 18269339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages.
    Shi GP; Bryant RA; Riese R; Verhelst S; Driessen C; Li Z; Bromme D; Ploegh HL; Chapman HA
    J Exp Med; 2000 Apr; 191(7):1177-86. PubMed ID: 10748235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Destructive potential of the aspartyl protease cathepsin D in MHC class II-restricted antigen processing.
    Moss CX; Villadangos JA; Watts C
    Eur J Immunol; 2005 Dec; 35(12):3442-51. PubMed ID: 16259009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathepsin G is differentially expressed in primary human antigen-presenting cells.
    Stoeckle C; Sommandas V; Adamopoulou E; Belisle K; Schiekofer S; Melms A; Weber E; Driessen C; Boehm BO; Tolosa E; Burster T
    Cell Immunol; 2009; 255(1-2):41-5. PubMed ID: 19036358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity determinants of human cathepsin s revealed by crystal structures of complexes.
    Pauly TA; Sulea T; Ammirati M; Sivaraman J; Danley DE; Griffor MC; Kamath AV; Wang IK; Laird ER; Seddon AP; Ménard R; Cygler M; Rath VL
    Biochemistry; 2003 Mar; 42(11):3203-13. PubMed ID: 12641451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cathepsin S activity regulates antigen presentation and immunity.
    Riese RJ; Mitchell RN; Villadangos JA; Shi GP; Palmer JT; Karp ER; De Sanctis GT; Ploegh HL; Chapman HA
    J Clin Invest; 1998 Jun; 101(11):2351-63. PubMed ID: 9616206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocytosis targets exogenous material selectively to cathepsin S in live human dendritic cells, while cell-penetrating peptides mediate nonselective transport to cysteine cathepsins.
    Reich M; van Swieten PF; Sommandas V; Kraus M; Fischer R; Weber E; Kalbacher H; Overkleeft HS; Driessen C
    J Leukoc Biol; 2007 Apr; 81(4):990-1001. PubMed ID: 17261546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of specific cell permeable cathepsin G inhibitors resulted in reduced antigen processing in primary dendritic cells.
    Reich M; Lesner A; Legowska A; Sieńczyk M; Oleksyszyn J; Boehm BO; Burster T
    Mol Immunol; 2009 Sep; 46(15):2994-9. PubMed ID: 19615749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cathepsin cysteine proteases in cardiovascular disease.
    Lutgens SP; Cleutjens KB; Daemen MJ; Heeneman S
    FASEB J; 2007 Oct; 21(12):3029-41. PubMed ID: 17522380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo control of endosomal architecture by class II-associated invariant chain and cathepsin S.
    Boes M; van der Wel N; Peperzak V; Kim YM; Peters PJ; Ploegh H
    Eur J Immunol; 2005 Sep; 35(9):2552-62. PubMed ID: 16094690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of MHC II and CD1 antigen presentation: from ubiquity to security.
    Gelin C; Sloma I; Charron D; Mooney N
    J Leukoc Biol; 2009 Feb; 85(2):215-24. PubMed ID: 18809734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cysteine protease cathepsin S as a key step in antigen presentation.
    Liu W; Spero DM
    Drug News Perspect; 2004; 17(6):357-63. PubMed ID: 15334187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in the design of cathepsin S inhibitors.
    Wiener JJ; Sun S; Thurmond RL
    Curr Top Med Chem; 2010; 10(7):717-32. PubMed ID: 20337580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.